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and R. Stephanie Huang2,*
We sought to comprehensively and systematically characterize the relationship between genetic variation, miRNA expression, and
mRNA expression. Genome-wide expression profiling of samples of European and African ancestry identified in each population
hundreds of miRNAs whose increased expression is correlated with correspondingly reduced expression of target mRNAs. We scanned
30 UTR SNPs with a potential functional effect on miRNA binding for cis-acting expression quantitative trait loci (eQTLs) for the corre-
sponding proximal target genes. To extend sequence-based, localized analyses of SNP effect on miRNA binding, we proceeded to dissect
the genetic basis of miRNA expression variation; we mapped miRNA expression levels—as quantitative traits—to loci in the genome as
miRNA eQTLs, demonstrating that miRNA expression is under significant genetic control. We found that SNPs associated with miRNA
expression are significantly enriched with those SNPs already shown to be associated withmRNA.Moreover, we discovered that many of
the miRNA-associated genetic variations identified in our study are associated with a broad spectrum of human complex traits from the
National Human Genome Research Institute catalog of published genome-wide association studies. Experimentally, we replicated
miRNA-induced mRNA expression inhibition and the cis-eQTL relationship to the target gene for several identified relationships among
SNPs, miRNAs, and mRNAs in an independent set of samples; furthermore, we conducted miRNA overexpression and inhibition exper-
iments to functionally validate the miRNA-mRNA relationships. This study extends our understanding of the genetic regulation of the
transcriptome and suggests that genetic variation might underlie observed relationships between miRNAs and mRNAs more commonly
than has previously been appreciated.Introduction
Given the fundamental role of gene expression in biolog-
ical and pathophysiological processes, mechanisms under-
lying gene expression variation, including genetic variation
(e.g., expression quantitative trait loci [eQTLs]1,2), epige-
netic factors (e.g., miRNAs3 and methylation status4,5),
and environmental variables (e.g., chemicals, stress, and
drugs), have been extensively investigated. The complexity
of humanbiology suggests thatmanyof these factorsmight
participate in a context-dependent manner in the regula-
tion of gene expression.
The International HapMap consortium collected
samples from various ethnic populations around the
world.6 The 1000 Genomes Project,7 building on the
HapMap resource, embarked on the mission of providing
a comprehensive catalog of human genome sequence vari-
ation to facilitate discoveries of the genetic contribution to
human phenotypes. To date, genetic variants in the form
of millions of SNPs and thousands of copy-number vari-
ants (CNVs),8,9 transcription-level gene expression,1,10–12
and other phenotypic data (e.g., cellular sensitivity to
drugs13–17) have been made publicly available for many
of these samples. Collectively, these datasets provide an
unparalleled resource for the study of genotype-phenotype
relationships.
Likewise, recent studies have advanced our under-
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nous noncoding RNA molecules that have been shown to
be important post-transcriptional regulators of cognate
mRNA targets. Predicted to target a third of all human
mRNAs, they are known to mediate their effect through
translational repression or mRNA degradation. Further-
more, mRNA expression might be simultaneously altered
by more than one miRNA species.19 Extending these
studies of miRNA function, we conducted genome-wide
profiling of miRNA expression in samples of European
and African ancestry to enhance our understanding of
miRNA-mediated gene regulation, including dissection of
the genetic basis of miRNA expression variation, and to
explore its consequences for gene (mRNA) expression regu-
lation and human disease.Material and Methods
Cell Lines
Sixty unrelated CEU (Utah residents with ancestry from northern
andwestern Europe from the CEPH collection; HAPMAPPT01) and
60 unrelated YRI [Yoruba from Ibadan, Nigeria; HAPMAPPT03)
lymphoblastoid cell lines (LCLs) from the International HapMap
Project were purchased from the Coriell Institute for Medical
Research (Camden, NJ) for genome-wide discovery. In addition,
58 unrelated CEU III (HAPMAPPT06) and 58 unrelated YRI III
(HAPMAPPT04) LCLs were obtained from the same resource and
used for validation experiments. LCLs were maintained in RPMIChicago, IL 60637, USA; 2Section of Hematology/Oncology, Department of
ealth Studies, University of Chicago, Chicago, IL 60637, USA; 4Columbia
Genetics. All rights reserved.
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Figure 1. Distribution of the p Values for
the Association between a Potential
Confounder and miRNA Expression Level
in the HapMap CEU LCLs
(A) A Q-Q plot of the p values for the asso-
ciation between intrinsic cellular-growth
rate (generated from a mixed-effects
modeling of cellular proliferation) and
miRNA expression level shows that
cellular proliferation is not associated
with miRNA expression levels.
(B) A Q-Q plot of the p values for the asso-
ciation between EBV copy number and
miRNA expression level shows one miRNA
reaching significance in association with
EBV copy number.
(C) To test for the presence of significant
EBV confounding, we performed permuta-
tion analyses and generated a Q-Q plot for
each of 1,000 replicates (shown as gray
dots) and for the actual data (shown
as blue dots); we demonstrate that
the observed off-diagonal phenomenon
(shown in Figure 1B) is within what is ex-
pected by chance.1640 and 1% l-glutamine plus 15% fetal bovine serum (FBS) as
previously described.20
Obtaining SNP Genotype, mRNA Expression, and
miRNA Expression in Discovery samples
We conducted our analyses on common SNPs (minor allele
frequency [MAF] > 5%) identified in the HapMap CEU and YRI
samples.
Global baseline gene expression on 87 CEU and 89 YRI LCLs
were previously quantified with the Affymetrix GeneChip Human
Exon 1.0 STarray (Affymetrix exon array).21 A total of 12,747 tran-
script clusters (representing 10,830 genes) were utilized in this
study.1
Detailed methods on miRNA isolation and quantification were
described before.22 Information on data quality control (including
the result of an unsupervised hierarchical clustering of the sample-
by-miRNA-expression matrix for the detection of the presence of
batch effects) can be found in Appendix A and Figure S1, available
online. Baseline miRNA expression was evaluated in 107 HapMap
LCLs (53 CEU and 54 YRI) with the use of Exiqon miRCURY LNA
arrays v.10.0 (Exiqon array). Quantified signals were background
corrected with normexp with an offset value of 10 on the basis
of a convolutionmodel and were normalized with the global Low-
ess regression.23 After normalization and filtering, 201 miRNAs
were found to be expressed in these samples (a miRNA is consid-
ered to be expressed if at least 70% of all samples have an expres-
sion intensity value on the Exiqon arrays and if the average Hy3
intensity value for this miRNA across samples is greater than
100) (Figure S2). The genome-wide miRNA expression data have
been deposited into the Gene Expression Omnibus under acces-
sion number GSE34406.
Previously, certain nongenetic confounders (e.g., cellular
growth rate and Epstein-Barr virus [EBV] copy number) were re-
ported to substantially affect trait variability in LCLs.24 We there-
fore systematically investigated to what extent these potentialThe Americconfounders might contribute to variability in miRNA expression
given that relatively little is known about the impact of
these potential confounders on miRNA abundance levels (e.g.,
compared to mRNA transcript levels). We generated intrinsic
cellular-proliferation rates for these cell lines through mixed-
effects modeling as previously described;25 the intrinsic pheno-
type, intrinsicPhenotype(i), and a wide range of experimental
conditions were treated as random effects, and the covariate Xm
was treated as a fixed effect for a given cell line i and replicate k.
Yijk ¼ aþ intrinsicPhenotypeðiÞ þ conditionðjÞ þ
X
bmXm þ errorijk
EBV copy-number data were obtained from a previous publica-
tion from our group.26
For each potential confounder, we generated a quantile-quantile
(Q-Q) plot showing the distribution of p values for the association
between the putative confounder and miRNA expression in LCLs
(Figure 1). Each Q-Q plot also shows three lines corresponding to
various levels (0.05, 0.10, and 0.25) of false discovery rate (FDR).
Note from the growth-rate Q-Q plot (Figure 1A) that cellular prolif-
eration shows no significant effect on the expression levels of the
miRNAs examined, which dramatically contrasts with our recent
findings25 that nearly a third of all gene-expression traits are
significantly associated (FDR < 0.10) with cellular proliferation.
Furthermore, only one miRNA (miR-298, also known as MIR298
[HUGOGene Nomenclature Committee ID HGNC: 33634]) shows
a significant association with EBV copy number (Figure 1B). We
noted, however, that certain miRNAs are slightly above the y ¼ x
diagonal line on the EBV Q-Q plot, and this might suggest lower
p values than expected by chance. To determine whether this
observation indicates the presence of significant EBV confound-
ing, we conducted permutation analyses and plotted the Q-Q
plot for each of 1,000 replicates (shown as gray dots in
Figure 1C) in relation to the Q-Q plot for the actual data
(shown as blue dots in Figure 1C), and we demonstrated thatan Journal of Human Genetics 90, 1046–1063, June 8, 2012 1047
Figure 2. A Schematic Diagram of the
Analysis
(A) Genome-wide analysis for the identifi-
cation of SNPs located in the 30 UTR of
potential miRNA targets.
(B) Genome-wide evaluation of SNP-
miRNA-mRNA relationships.the observed off-diagonal phenomenon is well within what is
expected by chance.
Genome-wide Interrogation of SNPs Located in the 30
UTR of a Gene that Might Affect miRNA Binding
Figure 2A demonstrates the work flow of this analysis.We first con-
ducted a pairwise linear-regression analysis between the expres-
sion of each of 201 miRNAs (as predictors) and that of each of
12,747 transcript clusters. Those mRNAs whose expression
showed significant negative association with miRNA expression
(consistent with a particular model of miRNA targeting) with the
use of FDR for multiple testing (FDR < 0.05)27 were selected and
carried forward for further analysis. SNPs located in the 30 UTR
of these mRNAs were identified through dbSNP (hg version 18).
Under the assumption of an additive genetic model, analyses of
the association between genotype and mRNA expression were
then performed between these 30 UTR SNPs and the corresponding
mRNA. Using a Bonferroni adjustment (for the 5,043 and 5,602
SNPs located in the 30 UTRs of 491 CEU mRNAs and 572 YRI
mRNAs, respectively), we searched for significant 30 UTR cis-acting
eQTLs that might affect miRNA-mediated regulation of the target
gene (in which the 30 UTR eQTL was detected). Subsequently,
we also examined four miRNA-mRNA interaction-prediction
algorithms (TarBase,28 miRBase,29 TargetScan,30 and Pictar31) to
determine the overlap with our findings. In addition, two other
databases, PolymiRTS32and Patrocles,33 which predict potential
SNP effects on 30 UTR miRNA bindings, were evaluated.
To experimentally confirm the relationships between miRNA
andmRNA and between 30 UTR SNPs and genes, we first quantified
selected miRNAs and mRNAs in an independent set of 58 CEU III
and 58 YRI III samples. Quantitative PCR (qPCR)methods were de-
signed for six genes (SLC23A2 [MIM 603791], IFI35 [MIM 600735],
BTLA [MIM 607925], GYPE [MIM 138590], TK2 [MIM 188250],
and TOMM22 [MIM 607046]) and 13 miRNAs (miR-30b
[MIR30B], miR-30d [MIR30D], miR-106a [MIR106A (MIM
300792)], miR-16 [MIR16-1 (MIM 609704)], miR-20a [MIR20A
(MIM 609420)], miR-106b [MIR106B (MIM 612983)], miR-15b
[MIR15B], miR-93 [MIR93 (MIM 612984)], miR-181a-2 [miR-
181a (MIR181A2 [MIM 612743])], miR-185 [MIR185], miR-886-
3p [VTRNA2-1], miR-186 [MIR186], and let-7i [MIRLET7I (MIM
612148)]) and were performed for 12 randomly selected discovery
HapMap samples. The qPCR results were compared to the exon-
array and Exiqon-array results as a validation of the method.
Only those qPCR results in significant positive correlation
(p < 0.05) with the array data were moved forward to quantifica-
tion with all the samples (i.e., 58 CEU III and 58 YRI III samples)
in the replication set. All miRNA primers were purchased from
Exiqon; Applied Biosystems Taqman primer and probe sets were
used for the quantification of mRNA expression. Real-time PCR1048 The American Journal of Human Genetics 90, 1046–1063, June 8, 2012was conducted with an ABI 7900 thermo-
cycler (Applied Biosystems, Foster City,
CA). Details for total RNA isolation,cDNA conversion, and PCR conditions were described in our
previous publication.22 A linear regressionwas performed between
the mRNA and miRNA expression (as a predictor) from the qPCR
results as well as between the 30 UTR SNP genotype (as a predictor)
and gene expression.
To functionally validate the miRNA and mRNA bindings, we
conducted miRNA overexpression and inhibition experiments
for a miRNA-mRNA pair (miR-30d and SLC23A2) in a randomly
selected HapMap YRI sample (GM18861). Specifically, the miRNA
mimic (catalog number MSY0000245) and the miRNA inhibitor
(catalog number MIN0000245) for miR-30d and the scrambled
control (AllStars Negative control, catalog number 1027292)
were purchased from QIAGEN. Detailed methods of the overex-
pression and inhibition experiments were described previously.22
Integrative Analysis of SNP, miRNA Expression, and
mRNA Expression
Figure 2B illustrates a schematic diagram of this analysis. First, we
set out to map miRNA eQTLs by performing genome-wide associ-
ation studies (GWASs) between more than two million SNPs and
201 miRNA expression phenotypes in CEU and YRI samples,
which were analyzed separately. SNPs located on the sex chromo-
somes were excluded from the current analysis. An additive
genetic model was assumed, and a p < 1010 cutoff (Bonferroni
adjustment based on the more than two million SNPs and the
201 miRNAs tested) was used for defining a significant miRNA-
eQTL finding. The location of the miRNA eQTLs and the pre-
miRNA for the corresponding mature miRNAs were examined
for the characterization of the positional distribution of miRNA
eQTLs relative to the corresponding pre-miRNA.
We performed a pairwise linear-regression analysis between
miRNA abundance level (as a predictor) and mRNA expression.
For each geneG andmiRNAm, we calculated the proportion of ex-
plained variance R2G,m from the linear model G ~m. Each gene was
also assigned a scoreMG defined as themaximumof the R
2
G,m over
all m’s:
MG ¼ max

R2G;m

:
For any given gene,MG measures the maximal proportion of ex-
plained variance from its association with a miRNA. We generated
the empirical cumulative distribution function (CDF) for MG,
CDFðxÞ ¼ #fG jMG%xg
total number of genes
;
compared the observed and expected distributions of the score
from permuted genome-wide gene-expression data, and per-
formed enrichment studies on those genes with the highest scores
(e.g., MG > 0.40).
For multiple testing of the miRNA-mRNA associations (in each
population and evaluated separately), an FDR approach was
used;27 we defined FDR< 0.05 as significant. From the distribution
of p values, FDR < 0.05 corresponds to p < 104. We also utilized
four miRNA-mRNA interaction-prediction algorithms (TarBase,
miRBase, TargetScan, and Pictar) for comparison with our expres-
sion-derived results. We have previously identified a set of mRNA
eQTLs in the LCL model system.1 To explore the functional signif-
icance of the miRNA eQTLs, we investigated the relationship
between genotype and mRNA expression in the CEU and YRI
samples separately for these SNPs. A raw p value less than or equal
to 104 for the SNP-mRNA relationships was used initially. We had
previously found that trait-associated SNPs are more likely to be
mRNA eQTLs than are a random set of SNPs starting at this p value
cutoff34 and to show a greater level of enrichment of mRNA eQTLs
at a more stringent mRNA-eQTL definition. Although this
threshold for defining mRNA-associated SNPs clearly falls short
of genome-wide significance (given the more than two million
SNPs and the more than 10,000 genes tested), we were interested
in investigatingwhethermiRNA-associated SNPs aremore likely to
predict mRNA transcript levels at this level than a random set of
allele-frequency-matched SNPs and whether this hypothesis holds
robustly to the threshold used (for the association between SNP
and mRNA expression; p < 106 was thus subsequently tested)
in these enrichment studies. Therefore, for a given list of
miRNA-associated SNPs and using 1,000 randomly generated
sets of allele-frequency-matched SNPs, we generated an empirical
distribution for the number of SNPs (in these sets) that predict
mRNA transcript levels at a given level. Furthermore, we used
the loose threshold to filter for ‘‘candidate relationships’’ (among
SNPs, miRNAs, and mRNAs) that can be validated in an indepen-
dent sample set.
We performed qPCR to confirm the miRNA-mRNA relationship
in an independent set of 58 CEU III and 58 YRI III samples for two
miRNAs (miR-378 [MIR378A (MIM 611957)] [Exiqon product
204347] and let-7d [MIRLET7D (MIM 612145)] [Exiqon product
204124 and Life Science product 204394]) and two genes (KCNIP2
[MIM 604661] [Life Science Hs01552690_g1] and CHPT1 [choline
phosphotransferase 1] [Life Science Hs01012465_m1]) by using
methods described earlier. We initially used the Exiqon primers
for qPCR of let-7d; however, because of the lack of correlation
between the qPCR results and the Exiqon-array findings, we
further performed qPCR by using the Life Science product for
the same miRNA. Furthermore, to replicate the genotype-expres-
sion association, we downloaded SNP genotype data from
HapMap for these Phase III CEU and Phase III YRI samples and per-
formed a linear regression—by assuming an additive genetic
model—between the genotype and either miRNA expression or
mRNA expression in the replication dataset.
Evaluation of SNP Effect on the miRNA-Processing
Machinery Genes and Downstream miRNA
Expression
We evaluated 52 genes known to be involved in the miRNA-pro-
cessing machinery.33 Using an FDR approach for multiple testing,
we tested for significant miRNAs associated with these genes that
are crucial to miRNA processing and biogenesis;27 FDR < 0.05 was
defined as significant. We also sought evidence for the role of
genetic variation in mediating the miRNA-mRNA relationships
for these genes by querying the SCAN database,35 which hosts
the results of our mRNA-eQTL studies on the HapMap CEU and
YRI samples, to identify SNPs associated with transcriptionalThe Americexpression for these genes in the separate CEU and YRI samples.
Genome-wide significance was defined with a stringent Bonfer-
roni criterion (based on 51 expressed genes and the more than
two million SNPs tested, p < 4.9 3 1010).Results
Genome-wide Interrogation of 30 UTR SNPs thatMight
Affect miRNA Binding
miRNA-mRNA Relationships
Genome-wide expression profiling in the CEU and YRI
samples identified 100 and 114 miRNAs (FDR < 0.05),
respectively, for which increased expression is associated
with decreased expression of 558 and 633 mRNAs, respec-
tively. See Figure S3 for the distribution of p values for the
negative associations between miRNA expression and
mRNA expression. As described in the Material and
Methods on the multiple-testing approach for the
miRNA-mRNA associations, FDR < 0.05 was used as the
definition of a significant association. Among these
miRNA-mRNA relationships, 16 miRNAs and 90 mRNAs
were implicated in both populations; see Table S1 for these
‘‘cross-population’’ relationships. The fact that we
observed several one-to-multiple relationships between
a single miRNA and more than ten mRNA expression
phenotypes in both CEU and YRI samples (e.g., miR-10a
[MIR10A (MIM 610173)], miR-148a [MIR148A (MIM
613786)], miR-181b-1 [MIR181B1, previously miR-181b
(MIM 612744)], and miR-363 [MIR363]) is consistent
with earlier studies that show that miRNAs might have
multiple expression targets.
30 UTR SNPs Potentially Affecting miRNA Binding to Target
mRNA
We scanned the 30 UTR SNPs with a potential functional
effect on miRNA binding for cis-acting eQTLs for the corre-
sponding target genes. We identified 5,043 and 5,602 SNPs
located in 30 UTRs of 491 CEU mRNAs and of 572 YRI
mRNAs, respectively. Using a Bonferroni adjustment
(based on the total number of cis tests for the 30 UTR
SNPs), we found a highly significant (p ¼ 7 3 1011) 30
UTR cis-acting eQTL, rs1056610, for TOMM22, for which
decreased expression level is also associated (FDR < 0.05)
with an increased expression level of the miRNA let-7i.
We then filtered for those 30 UTR SNPs that show associ-
ation (at the loose threshold of p < 0.01) with the mRNA
expression of the gene in which the 30 UTR SNP was found;
we used this threshold because we sought to determine
whether some of these nominally significant findings
might nevertheless be functionally validated and to estab-
lish how many are predicted by publicly available algo-
rithms. We identified 25 such 30 UTR SNPs (in 16 genes)
in CEU samples and 25 30 UTR SNPs (in 18 genes) in YRI
samples (Table 1). One 30 UTR SNP (rs10840 for the target
gene IFI35) was identified in both populations (p ¼ 2 3
104 and 5 3 104 in CEU and YRI samples, respectively).
In addition, we observed the following associations:
rs4240334 and GYPE in CEU samples (p ¼ 9 3 105;an Journal of Human Genetics 90, 1046–1063, June 8, 2012 1049
Table 1. 30 UTR SNPs that Potentially Affect miRNA Binding and Target-Gene Expression
Gene SNP miRNA
p Values
Population
Prediction Algorithm
SupportSNP and Gene miRNA and Gene
PIK3AP1 rs7448 miR-21 5.6 3 103 2.7 3 105 CEU
FRMD4A rs1060093 miR-148a 9.6 3 103 2.6 3 107 CEU
rs4748047 miR-185 5.5 3 103 9.5 3 105 CEU
miR-29b-1* 2.8 3 105 CEU
CAMK1D rs1644394 miR-148a 4.5 3 103 4.1 3 105 CEU Ypa1, Ypa2
ENDOD1 rs533669 miR-138 9 3 103 5.1 3 105 CEU Ypo
rs607666 9 3 103 CEU Ypo
ERC1 rs3741977 miR-223 1.8 3 103 5.1 3 107 CEU Ypa2
DDX51 rs10128884 miR-340 8 3 104 8.9 3 105 CEU
rs11246940 2.1 3 104 CEU
RBL2 rs3929 miR-223 4.5 3 103 1.5 3 105 CEU Ypo
IFI35 rs10840 miR-106a 2 3 104 1.9 3 105 CEU
miR-20a 8.4 3 105 CEU
miR-642 8.2 3 105 CEU
miR-106b 5 3 104 4.7 3 105 YRI
miR-15b 3.1 3 105 YRI
miR-93 5.2 3 106 YRI
PPP1R9B rs11365 miR-223 6.9 3 103 9.7 3 105 CEU Ypa1, Ypa2
LOC201164 rs14003 miR-10a 1 3 102 1.8 3 109 CEU
miR-181a 3.9 3 105 CEU
miR-181b 3.8 3 106 CEU
miR-363 7.6 3 105 CEU
GLUL rs7734 miR-10a 4.7 3 103 2.7 3 107 CEU
rs9347 miR-363 3.3 3 103 1.1 3 106 CEU
AP1S3 rs3099467 miR-181b 4.9 3 103 4.5 3 105 CEU
miR-363 3 3 105 CEU
GYPE rs4240334 miR-16 9 3 105 7.1 3 105 CEU Ypo
miR-185 6.1 3 105 CEU
TRAM2 rs2073181 miR-10a 1.5 3 103 2.5 3 105 CEU Ypo
rs2073182 miR-181b 1.4 3 103 3.9 3 105 CEU Ypo
rs3804498 miR-363 1.4 3 103 1.7 3 105 CEU Ypo
IQCE rs3735110 miR-363 4 3 103 5.3 3 105 CEU
rs3735114 5.5 3 103 CEU
ZFAT rs6982146 miRPlus_42780 1.9 3 103 7 3 105 CEU
rs9644464 3.3 3 103 CEU
rs16905194 3.2 3 103 CEU
ABTB2 rs2473930 miR-191 9.7 3 103 5.4 3 106 YRI Ypo
miR-423-3p 1 3 105 YRI
miR-425 3.4 3 107 YRI
miR-744 3.2 3 105 YRI
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Table 1. Continued
Gene SNP miRNA
p Values
Population
Prediction Algorithm
SupportSNP and Gene miRNA and Gene
EHD1 rs7948832 let-7i 9.2 3 103 7.3 3 105 YRI Ypo
miR-181a 7 3 106 YRI
miR-181b 1.5 3 105 YRI
miR-20b 3.8 3 108 YRI
miR-339-5p 5.5 3 105 YRI
miR-363 5.8 3 108 YRI
GNS rs674 miR-106b 1 3 103 2 3 105 YRI
rs12309081 5.4 3 103 YRI
C12orf5 rs11063101 miR-15b 5 3 104 4.4 3 105 YRI
rs12230757 miR-25 1.9 3 103 3.1 3 105 YRI
rs12823931 miR-93 9.8 3 103 8.6 3 105 YRI
TK2 rs3743712 miR-886-3p 5 3 106 1.6 3 105 YRI
miRPlus_17848 2.6 3 105 YRI
CALR rs1049481 miR-342-3p 2.1 3 103 1.1 3 105 YRI Ypo
SLC23A2 rs16990301 miR-10a 4.6 3 103 2.3 3 106 YRI Ypa2
miR-148a 1.5 3 105 YRI
miR-181a 2.4 3 105 YRI
miR-30b 6.7 3 105 YRI Ym
miR-30d 7.4 3 106 YRI Ym
miR-363 1.6 3 105 YRI
TOMM22 rs1056610 let-7i 7 3 1011 1.7 3 105 YRI Ypo
rs1056661 miR-186 1 3 107 2.4 3 105 YRI Ypo
rs5750668 3 3 104 YRI Ypo
HK2 rs943 miR-1 1.8 3 103 2.4 3 105 YRI Ypo
rs3821305 miR-22 2.2 3 103 5.4 3 105 YRI Ypo
PNPT1 rs782652 miR-342-3p 1.8 3 103 3.2 3 105 YRI Ypo
EPAS1 rs10495933 miR-15b 3.2 3 103 1.7 3 105 YRI Ypo
OGG1 rs1052133 miR-342-3p 9 3 106 1.7 3 105 YRI Ypo
BTLA rs2171513 miR-181a 4.1 3 103 4 3 105 YRI Ym, Ypo
DCBLD2 rs3796133 miR-549 7.7 3 103 5 3 105 YRI Ypa1, Ypa2, Ypo
AUTS2 rs12698938 miR-10a 3 3 104 4 3 105 YRI Ym, Ypa2
miR-363 1.7 3 105 YRI Ypa1
MEGF9 rs1043245 miR-191 5.5 3 103 1.8 3 106 YRI Ypa1, Ypa2
rs7040418 miR-425 5.5 3 103 1.1 3 105 YRI Ypo
MOBKL2B rs10116870 miR-191 9.1 3 103 5.1 3 105 YRI
Bold miRNAs and genes indicate that the negative correlation between themwas also observed in the other population (p< 104). The following abbreviations are
used: CEU, Utah residents with ancestry from northern and western Europe from the CEPH collection; YRI, Yoruba from Ibadan, Nigeria; Ypa1, Patrocles-predicted
cis-eQTL; Ypa2, Patrocles-predicted SNP being a putative target site of a miRNA; Ym, miRanda-predicted miRNA and mRNA binding; and Ypo, PolymiRTS-pre-
dicted SNP that might affect miRNA binding.Figure 3A) and rs3743712 and TK2 (p ¼ 5 3 106),
rs1056610 and rs1056661 each with TOMM22 (p ¼ 7 3
1011 and 1 3 107, respectively), and rs1052133 andThe AmericOGG1 (MIM 601982) (p ¼ 9 3 106) in YRI samples. See
Table 1 for the full list of these associations between
these 30 UTR SNPs and the mRNA expression of thean Journal of Human Genetics 90, 1046–1063, June 8, 2012 1051
Figure 3. Discovered and Replicated 30
UTR SNPs that Potentially Affect miRNA
Binding to the Corresponding Gene
(A and E) The relationship between
rs4240334 genotype and GYPE expression
in the discovery (CEU I/II) and replication
(CEU III) samples, respectively.
(B and F) The negative correlation between
the expression of miR-185 and of GYPE in
the discovery CEU I/II and replication CEU
III samples, respectively.
(C and G) The relationship between
rs16990301 genotype and SLC23A2
expression in the discovery (YRI I/II)
and replication (YRI III) samples, respec-
tively.
(D and H) The negative correlation
between the expression of miR-30d and
of SLC23A2 in the discovery YRI I/II
and replication YRI III samples, respec-
tively. Exiqon and Exon arrays were
used for obtaining miRNA and gene-
expression data, whereas real-time PCR
was used for the quantification of miRNA
and mRNA expression in the replication
samples.corresponding genes; in addition, the table lists only the
significant (negative) miRNA correlations (FDR < 0.05)
with mRNA expression.
30 UTR mRNA-Associated SNPs and Computational Predictions
From this set of 30 UTR SNPs that shownominal association
withmiRNA-associatedmRNAexpression (Table1),we then
examined whether any of the miRNA-mRNA relationships
we observed were predicted in publicly available prediction
algorithms. Indeed, somemiRNAs found by our expression
profiling to be negatively correlated with genes harboring
such mRNA-associated 30 UTR SNPs are also predicted by
miRBase as interacting with their cognate mRNAs; such
interactions include miR-10a and AUTS2 (MIM 607270),
miR-181a and BTLA, and miR-30b and miR-30d each with
SLC23A2 (Table 1 and Figure 3D). Furthermore, four such
mRNA-associated 30 UTR SNPs were confirmed by the Pa-
trocles algorithm (Table 1). Of the 49 30 UTR SNPs we iden-
tified as having a potential functional effect on miRNA
binding, the same database reproduces seven that poten-
tially affect eightmiRNAtargets. In addition, thePolymiRTS
algorithm (Table 1) identified 21 of these 49 30 UTR SNPs as
potentially affecting miRNA binding.1052 The American Journal of Human Genetics 90, 1046–1063, June 8, 2012Functional Validation: 30 UTR SNPs and
miRNA-mRNA Interaction
From the list of 30 UTR SNPs that
show nominal association with
mRNA expression as potential eQTLs
(Table 1), we performed qPCR on
a selection of top candidates (bold in
Table 1) in an independent replica-
tion set of HapMap Phase III CEU
(n ¼ 58) and Phase III YRI (n ¼ 58)
samples. In the CEU III samples, wereplicated the association between a 30 UTR SNP
(rs4240334) and GYPE as well as the measured expression
of the gene (p ¼ 0.023, Figure 3E). Furthermore, the nega-
tive correlation between expression levels of miR-185 and
GYPE (p ¼ 6.1 3 105, Figure 3B) was also replicated (p ¼
0.012, Figure 3F). In YRI samples, we found a SNP
(rs16990301) that cis-associated with SLC23A2 expression
in the YRI I/II samples (p ¼ 0.005, Figure 3C) and that
also associated with SLC23A2 expression in the YRI III
replication samples (p ¼ 0.049, Figure 3G). Furthermore,
we replicated the negative correlation between expression
levels of SLC23A2 and miR-30d in these YRI III samples
(p ¼ 0.049, Figure 3H). Note that the relationship between
miR-30d and SLC23A2 is predicted by miRBase; however,
the replicated relationship between expression of GYPE
and miR-185 is not.
To further validate the miRNA-mRNA interaction
between miR-30d and SLC23A2, we performed overexpres-
sion and inhibition tests. We found that the addition of
miR-30d mimic resulted in an increase in the amount of
miR-30d and a decrease in SLC23A2 expression in cells at
24 hr. These findings were further supported by miR-30d
Figure 4. Effect of miRNA Mimic and Inhibitor
on the Expression of miR-30d and Target Gene
SLC23A2
miR-30d is represented in (A), and SLC23A2 is
represented in (B). These experiments were per-
formed in a randomly selected LCL sample
(GM18861). The x axis describes the type of
experiment. The y axis illustrates the percent
change in expression level when compared to
scramble control in each experiment either for
miRNAs or for target genes.inhibition experiments that led to a decrease in miR-30d
expression and an increase in SLC23A2 expression
(Figure 4).
Genetic Regulation of miRNA Expression
miRNA eQTLs: The Genetic Basis of miRNA Expression Variation
Having identified 30 UTR SNPs that might affect miRNA
binding to target mRNA, we then performed GWASs to
map miRNA expression variation to loci in the genome.
Using a Bonferroni adjustment (based on the more than
two million SNPs and the 201 miRNAs tested), we identi-
fied 31 genome-wide significant (p < 1 3 1010) SNP asso-
ciations with miRNA expression (Table S2). For example,
we identified in CEU samples a set of SNPs each associated
with the expression of miR-671-5p (MIR671, previously
miR-671) at p < 1 3 1011 and a highly significant (p ¼
2.5 3 1012) association between rs17782814 and
miR-129-5p (MIR129-2, previously miR-129). Similarly,
in YRI samples, we found genome-wide significant (p <
1 3 1010) associations between miRNA expression (hsa-
miR-765 [MIR765], hsa-miR-671-5p, hsa-miR-671-5p,
hsa-miR-671-5p, miR-129-1-3p [MIR129-1, previously
hsa-miR-129*], miR-155-3p [MIR155, previously hsa-
miR-155*], and hsa-miR-658 [MIR658]) and genetic varia-
tion (rs10998703, rs6086165, rs6038925, rs2206401,
rs532453, rs11900127, and rs1374502, respectively). We
refer to these miRNA expression-associated SNPs meeting
genome-wide significance as ‘‘miRNA eQTLs.’’
In the CEU and YRI samples, 153 and 47 SNPs, respec-
tively, were associated at a suggestive threshold (p < 1 3
108) with 15 (7.4%) and 21 (10.4%) miRNA expression
phenotypes, respectively. At a threshold of p < 1 3 106,
1,792 SNPs from CEU samples and 1,390 SNPs from YRI
samples were associated with 131 (65.1%) and 154
(76.6%) miRNA expression phenotypes, respectively.
Among these, a number of miRNA-associated SNPs were
associated with the same miRNA (e.g., miR-30b* and
miR-671-5p) in both populations. The chromosomal loca-
tion of these miRNA-expression-associated SNPs (p < 1 3
108) is illustrated in Figure 5.
Genomic Properties of miRNA-Associated SNPs
We found that the majority of miRNA eQTLs (p < 1 3
1010) trans-associated with mature miRNA expression.
No miRNA eQTLs were found in the region defined by
the mature miRNA.The AmericmiRNA eQTLs Are Enriched with mRNA eQTLs
Our group has previously identified a set of mRNA eQTLs
in these HapMap cell lines.35 To further evaluate the rela-
tionship between the observed miRNA-associated SNPs
and the mRNA eQTLs, we asked to what extent the
miRNA-associated SNPs (at suggestive p < 1 3 108) iden-
tified in this study influence global gene expression. We
found that 25% and 18% of such miRNA-associated SNPs
are also predictive of mRNA expression at p % 1 3 104
in CEU and YRI samples, respectively. This level of overlap
is a significant enrichment (p ¼ 0.027 in CEU samples and
p ¼ 0.025 in YRI samples) of mRNA-associated SNPs
among miRNA-associated SNPs on the basis of simulations
(n ¼ 1,000) with allele-frequency-matching SNPs; the
simulation procedure is as previously described34 (the
details of its application in this particular context are
found in the Material and Methods). At a more stringent
threshold for association with mRNA expression (p < 1 3
106), the level of overlap between miRNA-associated
SNPs and mRNA-associated SNPs becomes even more
significant (enrichment is p < 0.001 in CEU samples and
p ¼ 0.02 in YRI samples). Figure 6, for example, illustrates
the results of this enrichment analysis in CEU samples, and
the observed count (represented as a black dot) of mRNA-
associated SNPs among the miRNA-associated SNPs is
significantly greater than expected (shown as the null
distribution) given the MAF distribution of the miRNA-
associated SNPs. Thus, we have confirmed a hypothesis
that is perhaps not unexpected: The miRNA-associated
SNPs identified in our study are significantly more likely
to predict mRNA-transcript levels than is a random set of
allele-frequency-matched SNPs. This observation is robust
to the threshold used for defining SNP-mRNA associations.
Genome-wide Integrative Analysis of SNPs, miRNA
Expression, and mRNA Expression: Discovery and
Validation
Having demonstrated a robust enrichment of mRNA-asso-
ciated SNPs among miRNA-associated SNPs, we proceeded
to quantify the proportion of mRNA expression variance
that might be attributed to miRNA expression. We also as-
signed to each gene a scoreMG (see Material and Methods)
defined to capture the proportion of explained variance
due to a miRNA predictor. Figure S4 shows the empirical
cumulative distribution function (CDF) for this score MG.an Journal of Human Genetics 90, 1046–1063, June 8, 2012 1053
Figure 5. The Chromosomal Location of miRNA-Expression-
Associated SNPs
A miRNA-associated SNP in CEU samples is denoted by a red line,
whereas that in YRI samples is denoted by a blue line. All SNPs
shown heremeet the criteria p< 13 108 withmiRNA expression.
Figure 6. miRNA eQTLs Are Significantly Enriched with mRNA
eQTLs
The histogram shows the empirical distribution from 1,000 sets
of allele-frequency-matched SNPs. The black dot represents the
observed overlap count. This plot illustrates the enrichment
of mRNA-associated SNPs in miRNA eQTLs in CEU samples
(p < 0.001).We performed enrichment analyses on permuted datasets
(n ¼ 10,000) of genome-wide gene-expression traits with
a preserved correlation structure to determine whether
the scores observed are greater than expected by chance.
Figure 7 shows the result of this analysis, which compares
the observed and expected distributions of the score. Note
how the higher explained variance attributable to miRNA
expression (quantified by MG) in the observed data
compares to what was expected. We then used
DAVID36,37 to conduct functional-annotation enrichment
analyses for the genes showing the highest proportion of
explained mRNA variation (i.e., MG > 0.40). We observed
a highly significant enrichment (Benjamini-Hochberg,
p < 3 3 103) for genes integral to the plasma membrane
(wherein the gene product is found to penetrate at least
one phospholipid bilayer of plasma membrane) and genes
intrinsic to the plasma membrane (i.e., the gene product is
located in the plasma membrane such that some cova-
lently attached portion of the gene product—e.g., part of
a peptide sequence or some other covalently attached
group such as a glycosylphosphatidylinisotol [GPI]
anchor—spans or is embedded in one or both leaflets of
the membrane).1054 The American Journal of Human Genetics 90, 1046–1063, JuneAll together, these various enrichment results from inde-
pendent data sources suggest that the miRNA effects we
observed on the mRNAs are not due to chance variation,
and they provide a quantitative assessment of the contri-
bution of the miRNAs to mRNA expression variability.
We then sought to determine whether some of the iden-
tified relationships among SNPs, miRNAs, and mRNAs
might be functionally validated. Focusing on the SNPs
that are both miRNA associated (p < 1 3 108) and
mRNA associated (p < 1 3 104), we identified a list of
12 SNPs, each of which is associated with the expression
of a miRNA (from a total list of four miRNAs) and the
expression of a gene (from a list of 14 genes) for which
the miRNA-mRNA relationship (either positive or nega-
tive) is significant (FDR < 0.05); all pairwise relationships
were among SNPs, miRNAs, and mRNAs identified in
CEU samples. Similarly, one SNP was associated with the
expression of one miRNA and four genes for which the
miRNA-mRNA relationship (either positive or negative) is
significant (FDR < 0.05), and all pairwise relationships
were identified in YRI samples (Table 2 and Figures
8A–8C). Among these findings, two of the miRNA-mRNA
relationships (miR-378 and KCNIP2; let-7d and CHPT1)
were also predicted by miRBase and therefore underwent
further functional evaluation.
In an independent set of 58 HapMap phase III CEU and
58 HapMap phase III YRI samples, we used qPCR to repli-
cate the relationship between genotype and mRNA expres-
sion for rs10022802 and CHPT1 (p ¼ 1 3 108 and p ¼
0.015 for CEU discovery and replication, respectively;
Figures 8A and 8B). We attribute the fact that we did not8, 2012
Figure 7. A Comparison of the Distribution of the Explained-
Variance Score between the Observed Data and Simulated Data
Note that we observed a higher explained-variance score (MG)
compared to what was expected.replicate the positive correlation between the expression of
let-7d and CHPT1 to the lack of correlation between the
two methods used for the quantification of let-7d expres-
sion (these two methods were the Exiqon assay and
qPCR with the Exiqon primers). Furthermore, the positive
correlation betweenmiR-378 and KCNIP2was replicated in
the separate samples (p ¼ 2 3 105 and p ¼ 0.002 for
YRI discovery and replication, respectively; Figures 8C
and 8D). We did not replicate the rs4687207-miR-378
and rs4687207-KCNIP2 relationships, suggesting that
they might be false discoveries.
Genetic variation, miRNA-Processing Machinery
Genes, and Downstream miRNA Expression
Fifty one of 52 genes important for nuclear- and cyto-
plasmic-miRNA processing and biogenesis are expressed
in the HapMap LCL samples (CPEB1 [MIM 607342] is the
exception). Using a strict Bonferroni correction (based on
the more than two million SNPs and the 51 expressed
genes tested), we found no genome-wide significant eQTLs
for the miRNA-processing genes. However, when we
restricted analysis to SNPs within the miRNA-processing
genes, we found four SNPs (rs7813 and rs910925, which
are missense SNPs, and rs2291779, an intronic SNP, all
within GEMIN4 [MIM 606969] and rs868224 located in
the intron of EIF2C2 [MIM 606229]) that trans-associated
with several downstream miRNA-processing genes (p %
104) without affecting their host-gene transcriptional
expression. The following observations are in the YRI
samples: rs7813 and rs2291779 are associated with
TNRC6B (MIM 610740) expression; rs910925 is associated
with CNOT1 (MIM 604917), TNRC6A (MIM 610739), and
TNRC6B expression; and rs868224 is associated withThe AmericDDX6 (MIM 600326) and SND1 (MIM 602181) expression.
Notably, among these four SNPs, the missense SNP rs7813
has previously been suggested to affect the miRNAome.38
At FDR < 0.05, we found significant associations
between the miRNA-processing genes and miRNA expres-
sion; such associations include DGCR8 (MIM 609030)
and miR-342-3p (MIR342) (in YRI) and DICER1 (MIM
606241) and miR-574-5p (MIR574) (in CEU) as well as
SMAD3 (MIM 603109) and miR-15b (MIR15B), SMAD3
and miR-744 (MIR744), and SMAD3 and miR-93 (in YRI).
This latter finding that a miRNA-processing gene
(SMAD3) is significantly associated (FDR < 0.05) with
multiple miRNAs continues to hold at nominal levels of
significance for the miRNA-mRNA relationship for the
miRNA-processing genes (Table S3).
miRNA eQTLs Are Associated with Complex Traits
We searched for correlations (r2 R 0.80) between miRNA
eQTLs identified in our study and complex-trait-associated
SNPs in the comprehensive National Human Genome
Research Institute (NHGRI) catalog of published
GWASs.39 We identified miRNA-associated SNPs that
have been associated with metabolic traits (e.g., total
cholesterol level and body mass index), neurological
diseases (e.g., amyotrophic lateral sclerosis [MIM 105400]
and Parkinson disease [MIM 168600]), and an autoim-
mune disorder (ankylosing spondylitis [MIM 106300]).
See Table 3 for the list of reported SNP associations from
published GWASs among our miRNA-associated SNPs,
most of which achieved genome-wide significance in the
initial study and were subsequently validated in an inde-
pendent replication study.
Discussion
Our study comprehensively investigated the genetic archi-
tecture of miRNA expression and genetic regulation of
miRNA-mRNA interaction on a genome-wide scale in the
HapMap cell lines. Our genome-wide analyses of 30 UTR
SNPs identified a comprehensive list of genetic polymor-
phisms showing evidence of influencingmiRNA regulation
of a gene. Our subsequent genome-wide miRNA-eQTL
mapping identified SNPs that potentially regulate miRNA
expression, mRNA expression, or both. In particular, our
study highlights the genetic basis of miRNA expression
variation and its contribution to transcriptional gene
expression variation. Importantly, these results can be inte-
grated into GWASs to provide mechanistic insights into
pathophysiology, therapeutic outcome, and other complex
traits.
Through an integrative analysis, we found (perhaps not
surprisingly) that miRNA-associated SNPs are enriched
with mRNA-associated SNPs. Our study explored each of
the following cases: (1) genetic variation mediates the
observed relationship between miRNA and mRNA; (2)
a SNP regulates miRNA expression, thereby altering
mRNA expression; or (3) a SNP regulates mRNA (e.g., thean Journal of Human Genetics 90, 1046–1063, June 8, 2012 1055
Table 2. SNP-miRNA-mRNA Relationships Identified in Our Study
SNP miRNA mRNA
p Values
PopulationSNP and miRNA SNP and mRNA miRNA and mRNA
rs4687207 miR-378 # CD38 8.1 3 109 1 3 105 1.8 3 105 YRI
KCNIP2 # 6 3 105 2 3 105 YRI
MTTP 2 3 105 4.9 3 105 YRI
RAPGEF2 4 3 105 9.6 3 105 YRI
rs10022802 let-7d # C10orf33 1.2 3 109 1 3 105 7 3 107 CEU
CHPT1 # 1 3 108 3.8 3 106 CEU
FADS2 6 3 107 2.5 3 107 CEU
IFI6 5 3 105 4.1 3 105 CEU
MAPK13 2 3 105 4.1 3 105 CEU
OAS3 7 3 105 5.2 3 105 CEU
RAPGEF2 4 3 105 1.6 3 107 CEU
SGMS1 1 3 105 2.3 3 105 CEU
TCL1A 4 3 106 2.4 3 109 CEU
rs4276463 mir-513a-5p CABC1 4.5 3 109 4 3 105 2.4 3 106 CEU
CHST11 2 3 105 1.1 3 105 CEU
rs11780970 let-7f C10orf33 9.2 3 109 5 3 106 2.1 3 107 CEU
DNAJC12 3 3 107 1.3 3 108 CEU
RAPGEF2 1 3 104 1.3 3 105 CEU
TCL1A 6 3 105 1.5 3 105 CEU
rs11986069 let-7f C10orf33 9.2 3 109 5 3 106 2.1 3 107 CEU
DNAJC12 3 3 107 1.3 3 108 CEU
RAPGEF2 1 3 104 1.3 3 105 CEU
TCL1A 6 3 105 1.5 3 105 CEU
rs460608 let-7f C10orf33 9.2 3 109 5 3 106 2.1 3 107 CEU
DNAJC12 3 3 107 1.3 3 108 CEU
RAPGEF2 1 3 104 1.3 3 105 CEU
TCL1A 6 3 105 1.5 3 105 CEU
rs7015737 let-7f C10orf33 7 3 109 3 3 106 2.1 3 107 CEU
CDKN2C 1 3 104 6.7 3 105 CEU
DNAJC12 2 3 106 1.3 3 108 CEU
FADS2 1 3 104 5.2 3 105 CEU
RAPGEF2 2 3 105 1.3 3 105 CEU
TCL1A 1 3 105 1.5 3 105 CEU
rs7196984 miR-191 ZYX 4.7 3 1010 1 3 104 8.6 3 105 CEU
rs7198753 6.4 3 1010 CEU
rs13331459 4.7 3 1010 CEU
rs17698789 4.7 3 1010 CEU
rs17770916 4.7 3 1010 CEU
rs1221892 let-7f C10orf33 9.3 3 1010 4 3 106 2.1 3 107 CEU
DNAJC112 7 3 105 1.3 3 108 CEU
# indicates that the miRNA-gene relationship is predicted by miRanda. The following abbreviations are used: YRI, Yoruba from Ibadan, Nigeria; and CEU, Utah
residents with ancestry from northern and western Europe from the CEPH collection.
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Figure 8. Discovered and Replicated
Relationships between SNPs, miRNA,
and mRNA
(A and B) The relationship between the
rs10022802 genotype and CHPT1 expres-
sion in the CEU I/II discovery (A) and
CEU III replication (B) samples.
(C andD) The positive correlation between
miR-378 and KCNIP2 expression in the
discovery (C) and replication (D) YRI
samples.genes involved in nuclear- and cytoplasmic-miRNA pro-
cessing examined here) expression, thereby altering
miRNA expression downstream. Each of these scenarios
demonstrates the importance of genetic variation in the
interaction between miRNA and mRNA expression. Only
about 20% of the observed miRNA-associated SNPs are
associated with mRNA. Because miRNAs might mediate
translational repression, it is possible that many of the
identified miRNA eQTLs might also act as protein eQTLs,
and this warrants the evaluation of these miRNA eQTLs
for their role in protein expression.
To date, most of the research efforts that have investi-
gated the genetic mechanisms underlying miRNA-mRNA
interactions have been focused on the 30 UTRs of the
miRNA target genes. SNPs in these 30 UTRs were found to
be under stronger negative selection than 30 UTR SNPs in
non-miRNA targets, suggesting that genetic polymor-
phisms in 30 UTRs are important for miRNA function.40
Furthermore, a recent study has reported that SNPs in
miRNA target sequences might interact with miRNAs to
affect the variability of gene expression.40 There have
been several such recent studies exploring this phenom-
enon. For example, Richardson et al. focused on SNPs
mapping to the miRNA-recognition elements (MREs) in
the 30 UTR of the miRNA targets, particularly those in the
MRE seed site (MRESS).41 Thomas et al. developed a compu-
tational approach to predict the effects of SNPs on miRNA
binding sites, and in this approach, all SNPs in the 30 UTR
of the target gene were evaluated simultaneously.42 In
addition, two other databases, PolymiRTS32 and Pa-
trocles,33 provide convenient online tools for querying
potential SNP effects on miRNA binding to 30 UTRs of
known genes. In this study, we also performed a compre-
hensive scan of the 30 UTRs for SNPs that could have
a potential effect on miRNA binding and that could thusThe American Journal of Human Geaffect miRNA regulation of the prox-
imal target mRNA. A subset of our
findings was confirmed by these data-
bases. It is worth noting that these
databases and tools are largely
premised on in silico evidence (e.g.,
sequence conservation). Our study,
on the other hand, provides addi-
tional evidence for genetic control
of miRNA-mRNA binding throughexperimental data consisting of both miRNA expression
and mRNA expression. One limitation of some existing
tools is that their predictions are based on SNPs in the
‘‘seed’’ region of the miRNA target sites so that only SNPs
that meet this requirement are presumed to affect the
base pairing between the miRNA and the cognate target
mRNA. However, it has been demonstrated that SNPs
outside of these ‘‘seed’’ regions might also affect miRNAs
that bind either upstream or downstream of the SNP.43
We functionally validated a number of these SNPs as
cis-acting eQTLs for their target genes and replicated the
inhibitive effect of the miRNA on the target mRNA in an
independent set of samples.
Through our overexpression and inhibition experi-
ments on miR-30b, we provided additional functional
support for its effect on the target mRNA, SLC23A2.
SLC23A2 (solute carrier family 23 [nucleobase trans-
porters], member 2) encodes a transporter that plays an
important role in vitamin C absorption and distribu-
tion.44 Genetic variants within this gene region have
been reported to be associated with the risk of preterm
delivery,45 lymphoma,46 advanced colorectal adenoma
and gastric cancer,47,48 and HPV16-associated head and
neck cancers.49 We found a SNP (rs16990301) that was
located in the 30 UTR of SLC23A2 and that was cis-associ-
ated with the expression of the gene in the HapMap YRI
samples (p ¼ 0.005). This association was not observed
in CEU samples because of the difference in MAF (0.04
and 0.14 in CEU and YRI samples, respectively). We also
found six miRNAs whose increased expression inhibited
SLC23A2 expression in the YRI samples. The bindings
between miR-30b or miR-30d and SLC23A2 were predicted
by miRBase. In addition, the inhibitive effect of miR-148a
on SLC23A2 expression was also replicated in the CEU
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Table 3. Replicated Associations between miRNA-Associated SNPs and Complex Traits
SNP
miRNA
Target Complex Trait
Complex-Trait
GWAS Sample Size
p Values
Replication Status
of SNP-Complex-Trait
Association
SNP-miRNA
Association
SNP-Complex-Trait
Association
rs10488031 miR-335 QT interval 2,325 Europeans 1.3 3 108 2 3 106 ND
rs7577851 miR-9* Parkinson disease
(age of onset)
857 white familial
cases and 440 white
idiopathic cases
3.1 3 106 9 3 106 þ
rs12970134 miR-320a body mass index 80,969 individuals 4.0 3 106 1 3 1012 þ
rs10206899 miR-933 serum creatinine 23,812 individuals of
European descent
4.5 3 106 1 3 1015 þ
rs13538 miR-933 chronic kidney disease 67,093 individuals of
European descent
4.5 3 106 5 3 1014 þ
rs11209026 let-7d ankylosing spondylitis 2,053 cases of European
descent and 5,140 controls
of European descent
4.8 3 106 9 3 1014 þ
rs11209026 miR-20a ankylosing spondylitis 2,053 cases of European
descent and 5,140 controls
of European descent
9.6 3 106 9 3 1014 þ
rs3846662 miR-222 total cholesterol 22,562 individuals 3.5 3 108 3 3 1019 ND
rs3846662 miR-221 total cholesterol 22,562 individuals 1.1 3 107 3 3 1019 ND
rs11590090 miR-150* hyperactive-impulsive
symptoms
909 trios 1.0 3 106 3 3 106 ND
rs1541160 miR-29b amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 3.0 3 106 2 3 108 þ
rs1541160 miR-520d-5p amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 3.8 3 106 2 3 108 þ
rs6420094 miR-665 chronic kidney disease up to 67,093 individuals
of European descent
4.3 3 106 1 3 1014 þ
rs1541160 miR-20b amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 5.0 3 106 2 3 108 þ
rs10514718 miR-26b major depressive
disorder
1,020 European cases and
1,636 European controls
5.8 3 106 4 3 106 ND
rs7577894 let-7e amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 6.6 3 106 1 3 106 þ
rs1541160 miR-22 amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 7.1 3 106 2 3 108 þ
rs2281135 miR-19a plasma level of liver
enzymes
7,751 European white
individuals
7.8 3 106 8 3 1016 þ
rs1541160 miR-17 amyotrophic lateral
sclerosis
1,821 cases versus 2,258
controls
8.0 3 106 2 3 108 þ
rs1541160 miR-106a amyotrophic lateral
sclerosis
1,821 cases and 2,258 controls 9.3 3 106 2 3 108 þ
rs167769 miR-335 eosinophilic esophagitis
(pediatric)
181 adolescent cases and
1,974 adolescent controls
of European descent
9.9 3 106 2 3 106 þ
The following abbreviation is used: ND, not done.In addition to the SNPs in the 30 UTR of a miRNA target,
Gong et al. cataloged a list of 757 SNPs located in or near
pre-miRNA regions. They found that 50 of these SNPs are
located in 41 miRNA seed regions, and they experimen-
tally validated seven of these SNPs for their effect on
miRNA target binding.50 Six of these seven SNPs are part
of the HapMap SNPs we examined, although none of
them were associated with the expression of the putative1058 The American Journal of Human Genetics 90, 1046–1063, Junetarget genes (SEMA3F [MIM 601124], BCL2 [MIM
151430], or ATP6V0E1 [MIM 603931]) in the HapMap
samples at the p < 104 threshold. This might be due, in
part, to the tissue specificity of gene and miRNA expres-
sion. Our group has previously identified a set of 33
miRNAs that demonstrated significant differences in
expression levels between the HapMap CEU and YRI
samples.22 In that study, we examined 2,770 SNPs showing8, 2012
high population differentiation (based on Fisher’s fixation
index, Fst) and found a subset that might contribute to the
observed differential miRNA expression. This study builds
on the earlier study by conducting a comprehensive
genome-wide analysis of SNP effect on miRNA regulation.
Furthermore, in contrast to earlier studies that consid-
ered sequence-based analyses (e.g., negative selection or
miRNA-recognition elements) of SNPs in miRNA regions
(such as pre-miRNAs or target sites), this study utilized
genetic mapping of miRNA expression phenotypes as
quantitative traits to characterize the genetic basis of
miRNA expression variation. Importantly, our genome-
wide analyses have shown that SNPs that lie outside of
miRNA regions (e.g., pre-miRNAs or target sites), which
have been the focus of most (localized) analyses of
SNP effect on miRNAs, might significantly influence
miRNA expression variation and thus alter miRNA-target
interactions.
From our miRNA-eQTL mapping, we found that a SNP,
rs4687207, is associated with miR-378 expression. This
miRNA is also associated with four mRNA expression
phenotypes, including those of KCNIP2, CD38 (MIM
107270), MTTP (MIM 157147), and RAPGEF2 (MIM
609530), in the YRI samples. The relationship between
miR-378 and KCNIP2 is predicted by miRBase and was
replicated by our study in an independent set of YRI
samples. KCNIP2 (Kv channel interacting protein 2)
encodes a member of the family of voltage-gated potas-
sium (Kv) channel-interacting proteins (KCNIPs), which
belong to the recoverin branch of the EF-hand superfamily.
Members of this protein family are small calcium-binding
proteins and might regulate A-type currents (hence,
neuronal excitability) in response to changes in intracel-
lular calcium. It has been shown that the increased expres-
sion of KCNIP2 attenuates cardiac hypertrophy,51 and
a defect in this gene confers susceptibility to ventricular
tachycardia.52 One miRNA, miR-133a, was shown to
protect against myocardial fibrosis and modulate electrical
repolarization through its effect on KCNIP2.53 In addition,
miR-378 was reported to play a role in the development of
cardiac hypertrophy.54 Interestingly, a recent report
confirms the role of miR-378 in myoblast differentia-
tion,55 suggesting a potential link between miR-378 and
KCNIP2 in cardiac tissue.
In CEU samples, a SNP (rs10022802) was found to asso-
ciate with the expression of let-7d (p ¼ 1 3 109) and nine
target mRNAs. The relationship between let-7d and CHPT1
is predicted by miRBase. CHPT1, choline phosphotransfer-
ase 1, has been found to be overexpressed in breast cancer
cell lines relative to the nontumorigenic cell lines,56
whereas let-7d expression variability has been reported in
different cancers, including breast,57 lung,58 and ovarian
cancers59 and acute promyelocytic leukemia.60
A polymorphism (829C>T) in the 30 UTR of dihydrofo-
late reductase (DHFR, [MIM 126060]) was previously
reported to affect miR-24 binding and result in DHFR over-
expression and methotrexate resistance.43 Adams et al.The Americshowed that variant carriers of an ESR1 30 UTR SNP could
increase the repression of miR-206 on ESR1 in breast
cancer cell lines.61 We did not replicate these findings in
our model possibly because we evaluated LCLs, in which
miR-24 is not expressed, as opposed to fibrosarcoma cells,
Chinese hamster ovary cells, or MCF7 cells.
We also conducted a systematic study of 51 genes impor-
tant for miRNA processing and biogenesis. These genes are
crucially involved in nuclear- and cytoplasmic-miRNA pro-
cessing. They include the core components—namely,
DROSHA (MIM 608828), an RNase III enzyme, and
DGCR8/Pasha—of the microprocessor complex that crops
the pri-miRNA into a hairpin-structured precursor miRNA
(pre-miRNA); XPO5 (MIM 607845), which transports the
pre-miRNA into the cytoplasm; andDICER1, a cytoplasmic
RNase III enzyme that dices the pre-miRNA into the ~22
nucleotide miRNA duplex.62 We hypothesized that genetic
polymorphisms that perturb the expression of genes in
this miRNA-processing machinery probably influence
miRNA expression. The SNP rs7813, which is a missense
polymorphism within GEMIN4 and which was previously
reported to affect the miRNAome,38 was identified by our
integrative analysis to associate with the expression of
downstream TNRC6B, which plays an important role in
the miRNA gene-silencing process.63 Notably, we found,
perhaps not surprisingly, that a miRNA-processing gene
(SMAD3) might influence, positively or negatively, the
expression of multiple miRNAs. Furthermore, potential
eQTLs for DICER1 or DROSHA expression were also found
to affect potential target miRNAs (Table S3). These findings
suggest a plausible mechanism for the trans-relationships
associated with miRNA eQTLs.
Finally, we hypothesized that miRNA eQTLs are likely to
make a contribution to disease pathogenesis and that
incorporating them in GWASs might yield functional
insights into otherwise anonymous associations. We thus
sought mechanistic hypotheses for published associations
between genetic variation and disease by utilizing the
miRNA-associated SNPs identified in our study. The poten-
tial mechanistic links between miRNA-related SNPs
and pathophysiology are supported by several recent
studies.41,42 For example, Richardson et al. found 39 SNPs
that potentially alter MRESSs and thus influence target-
gene expression and contribute to increased disease
risk.41 Thomas et al. identified several SNPs that are in
linkage disequilibriumwith those that might affect miRNA
binding and that are associated with the risk of developing
breast cancer, asthma, and Parkinson disease.42 Our find-
ings, which extend these observations that are localized
tomiRNA regions (specifically, target sites and pre-miRNAs)
through genome-wide miRNA-expression profiling,
provide significant evidence for the role of genetic-varia-
tion-mediated regulation of miRNA expression in the
etiology of a broad spectrum of human complex pheno-
types, including neurodegenerative diseases, metabolic
traits, and autoimmune disorders. Several examples are
worth highlighting. The SNP rs7577851 has been foundan Journal of Human Genetics 90, 1046–1063, June 8, 2012 1059
to be reproducibly associated with Parkinson disease.64
This SNP finding followed an earlier study,65 which had
implicated the PARK3 (MIM 602404) linkage region
located in chromosomal region 2p13. Our study identified
rs7577851 as a miR-9*-associated SNP. Remarkably,
a recent study showed the potential role of miR-9-based
gene-regulatory mechanisms in adult neurons and neuro-
degenerative states.66 We also identified two SNPs—
rs10206899 reproducibly associated with serum creatinine
(p ¼ 1 3 1015) and with chronic kidney disease (p ¼
5.0 3 105)67 and rs13538 reproducibly associated with
chronic kidney disease (p ¼ 5 3 1014)68 in two indepen-
dent studies—that target the miRNA miR-933. Our study
strongly supports the importance of SNP-mediated control
of miRNA expression (in particular, it implicates miR-933)
in renal function and susceptibility to chronic kidney
disease.
There are caveats to our study. First, the negative miRNA-
mRNA relationships observed in our study reflect only the
effect of miRNAs on mRNA stability or degradation rather
than on protein translation. Second, given the model
system utilized in this study, some of the miRNA-eQTL
findings might be tissue specific. Nevertheless, in addition
to previously implicated relationships that our study
experimentally confirmed, we demonstrated—through
extensive enrichment studies by using functional-annota-
tion categories as well as permuted datasets of genome-
wide gene-expression traits—that the miRNA effects
observed on mRNA expression in the model system are
not due to chance variation. Finally, it has been shown
that EBV used in establishing LCLs might affect gene69 or
miRNA expression (e.g., decreased miR-20070 and
increased miR-29b71). However, the miRNAs and mRNAs
highlighted in our study were not among those affected
by EBV, and indeed, we developed an easily extensible
approach to investigating the degree to which potential
confounders might contribute to variability in miRNA
expression. Consequently, we report here a substantial
difference in the impact of nongenetic confounders
(specifically, cellular proliferation) on miRNA and mRNA
expression levels.
In summary, we identified in the 30 UTR of genes a set
of SNPs that might affect miRNA regulation of cognate
targets. An extended genome-wide analysis investigated
the genetic basis of miRNA expression variation and
explored its effect on gene (mRNA) regulation. We identi-
fied genetic variants that are associated with the expres-
sion of genes critical to miRNA processing and biogenesis
and that thereby influence miRNA expression. Finally,
by examining trait-associated SNPs from the NHGRI
catalog of published GWASs, this study highlights the
importance of SNP-mediated control of miRNA expres-
sion in a range of complex human diseases. Collectively,
our findings confirm that the role of genetic variation
as an important contributing mechanism of gene regula-
tion can be extended to include those that are miRNA
mediated.1060 The American Journal of Human Genetics 90, 1046–1063, JuneAppendix A: Quality Control of Genome-wide
miRNA Expression Quantification
All cell lines used in this study were grown in four batches
of 25–30 LCLs per batch. A randomly chosen LCL
(GM18508) was used as a batch control. This control LCL
was thawed and grown with each batch, resulting in four
different measurements (18508A, 18508B, 18508C, and
18508D). Total RNA was isolated for all 110 samples (106
unique LCLs and 18508A, 18508B, 18508C, and
18508D). RNA quality and quantity were evaluated with
the Agilent 2100 Bioanalyser and NanoDrop. The
following criteria were used prior to Exiqon-array quantifi-
cation: (1) for RNA integrity, RNA integrity number (RIN)>
8; (2) for protein contamination, 260/280 ratio > 1.8; and
(3) for contamination with organic compounds, 260/230
ratio > 1.8.
To detect possible batch effects, unsupervised hierar-
chical clustering was performed on the sample-by-
miRNA-expression matrix for miRNAs with log2(Hy3/
Hy5) ratios that meet the filtering criteria on variation
across the LCL samples (standard deviation > 0.05).
Figure S1 is a heat map illustrating the result of the two-
way hierarchical clustering of the miRNAs and the
samples; each row represents a miRNA, and each column
represents a sample. As the sample-clustering dendrogram
at the top shows, the miRNA abundance levels for the four
repeated measurements of the control LCL are grouped
together into a single tight cluster and suggest no signifi-
cant batch effect.Supplemental Data
Supplemental Data include four figures and three tables and
can be found with this article online at http://www.cell.com/
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